France Oncology Market Analysis: Cancer Diagnostics and Cancer Treatment Drugs, Therapy, Applications (Blood Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Bladder Cancer, Head & Neck Cancer, Prostate Cancer, and Others), Region: as Île-de-France, Auvergne-Rhône-Alpes, Nouvelle-Aquitaine, Occitanie, Hauts-de-France, Provence-Alpes-Côte d’Azur, Grand Est and others

License Type

France Oncology market size is estimates to be $XX million in 2022. Before the age of 75 in France, it is predicted that 35.5 percent of males and 25.1 percent of women will have cancer. Despite medical advancements and a high incidence among persons of working age, the number of survivors has been gradually rising. In France, cancer mortality is lower among women under the age of 70. It should be emphasized that although data are only available in five-year age groupings, 67 is the required retirement age in France for those employed in the public sector. In 2012, more than 1 million adults in France, or 2.5% of the population had survived cancer for five years.

2018 estimates for new cancer cases and fatalities in metropolitan France According to the estimate, 67,800 cancer deaths and 177,400 new cases of the disease occurred in women in France in 2018, compared to 204,600 cases and 89,600 deaths in males. According to the most recent WHO data, in 2020 France has a record of 35,657 or 7.46% mortalities from lung Cancers. France ranks #19 in the world with a 27,51 per 100,000 people age-adjusted death rate. Lung cancer is a significant contributor to the overall France oncology market.

In France, there are 50,000 new cases of breast cancer identified each year, and 11,000 people pass away from the disease. After a sudden rise, which can be partially attributed to the adoption of the screening program, the incidence rate has been declining for a while. The mortality rate has been continuously dropping during the 2000s.

According to the most recent WHO data, in 2020 France has a record of 9,573 or 2.00% mortalities from liver Cancer. France ranks #61 in the world with a 6.66 per 100,000 people age-adjusted death rate.

According to estimates, there are 11,000 new instances of bladder cancer in the general French population each year. In terms of cancer-related deaths, BCA ranks 10th for women and 7th for males. Ninety percent of instances of urothelial cell carcinoma are this prevalent histological subtype.

According to the most recent WHO data, in 2020 France has a record of 10,873 or 2.27% mortalities from prostate Cancer. France ranks #152 in the world with a 13.24 per 100,000 people age-adjusted death rate.

In France, the leading causes of cancer risk factors included smoking, alcohol use, poor diet, and being overweight. To assure a future reduction in the burden of cancer, the long latency time of the preventative program calls for immediate action.

France Oncology Market by States

Île-de-France
Auvergne-Rhône-Alpes
Nouvelle-Aquitaine
Occitanie
Hauts-de-France
Provence-Alpes-Côte d’Azur
Grand Est
Rest of France

France oncology market has been spilt into regions namely Île-de-France, Auvergne-Rhône-Alpes, Nouvelle-Aquitaine, Occitanie, Hauts-de-France, Provence-Alpes-Côte d’Azur, Grand Est & others.

France Oncology Market Segments

Datavagyanik has covered each oncology in detail in terms of market size, sales volume, growth forecast. The segment and sub segment level categorization covered in the report are:

Cancer Diagnostics
- Biopsy
- Imaging
- Immunohistochemistry
- Tumor Biomarkers Test
- In Situ Hybridization
- Liquid Biopsy
Cancer Treatment Drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and Others)
- Cancer Treatment Therapy
  - Targeted Therapy
  - Chemotherapy
  - Hormonal Therapy
  - Immunotherapy
  - Others
- Applications
  - Blood Cancer
  - Lung Cancer
  - Colorectal Cancer
  - Breast Cancer
  - Liver Cancer
  - Bladder Cancer
  - Head & Neck Cancer
  - Prostate Cancer
  - Others

Key questions answered in the France Oncology Market Analysis Report:

What is the overall oncology market size in France and how is the demand rising and what is market for each cancer type (Blood Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Bladder Cancer, Head & Neck Cancer, Prostate Cancer, Others)?
What is the market size for cancer diagnostics (Biopsy, Imaging, Immunohistochemistry, Tumor, Biomarkers Test, In Situ Hybridization, Liquid Biopsy) in France?
What is the market size for cancer treatment drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and Others) in France?
What is the market size for cancer treatment by therapy (Targeted Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy, Others) in France?
Who are the top market players by market share, in each product segment?
Which is the fastest growing business/ product segment?
What should be the business strategies and Go to Market strategies?

Oncology in France: Report Deliverables

Summary Statistics
- Oncology in France Market Attractiveness Analysis

Oncology Diagnostics Market
Oncology Drugs
Therapies/Treatment Type

Oncology in France Market Analysis, by Segment (state level analysis)
- Overview
- Historical Market size ($Million), (2017 – 2021)
- Market size ($Million), and Forecasts (2022 – 2027)
Market Analysis by Segment (state level analysis)
- End Users (Hospitals, Diagnostics Centers, others)
- Application (Blood Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Bladder Cancer, Head & Neck Cancer, Prostate Cancer, Others)
Region wise analysis

Île-de-France revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
Auvergne-Rhône-Alpes revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
Nouvelle-Aquitaine revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
Occitanie revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
Hauts-de-France (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
Provence-Alpes-Côte d’Azur (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
Grand Est (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)
Rest of France revenue & volume (Cancer Diagnostics and Cancer Treatment Drugs, Therapy)